size
Sponsors
Farmaceutici Damor S.p.A., Zenas Biopharma (USA) LLC
Conditions
Non-active Secondary Progressive Multiple Sclerosis (SPMS)PRIMARY CHRONIC VENOUS DISEASE OF THE LOWER LIMBSPrimary Progressive Multiple Sclerosis (PPMS)
Phase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Not yet recruitingCTIS2025-524316-11-00
Target: 126Updated: 2026-05-19
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Not yet recruitingCTIS2025-524322-18-00
Target: 177Updated: 2026-06-23
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF CLR-07-23 (HEPARAN SULFATE 120 MG PROLONGED-RELEASE TABLETS) IN THE TREATMENT OF PRIMARY CHRONIC VENOUS DISEASE.
Not yet recruitingCTIS2024-514679-16-00
Target: 194Updated: 2026-10-23